Moreover, multiple studies have indicated that individuals diagnosed with lung cancer exhibit a higher propensity for developing resistance to PD-L1 inhibitors in comparison to other patient cohorts (Schoenfeld and Hellmann, 2020; Schoenfeld et al., 2021; Passaro et al., 2022). Here, CD274 is linked to lung cancer.